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ABSTRACT Some members of the genus Chlamydia, including the human pathogen
Chlamydia trachomatis, infect multiple tissues, including the genital and gastrointestinal
(GI) tracts. However, it is unknown if bacterial targeting to these sites is mediated by
multifunctional or distinct chlamydial factors. We previously showed that disruption of
individual large clostridial toxin homologs encoded within the Chlamydia muridarum
plasticity zone were not critical for murine genital tract infection. Here, we assessed
whether cytotoxin genes contribute to C. muridarum GI tropism. Infectivity and shedding
of wild-type (WT) C. muridarum and three mutants containing nonsense mutations in
different cytotoxin genes, tc0437, tc0438, and tc0439, were compared in mouse genital
and GI infection models. One mutant, which had a nonsense mutation in tc0439, was
highly attenuated for GI infection and had a GI 50% infectious dose (ID50) that was
1,000 times greater than that of the WT. GI inoculation with this mutant failed to elicit
anti-chlamydial antibodies or to protect against subsequent genital tract infection. Ge-
nome sequencing of the tc0439 mutant revealed additional chromosomal mutations,
and phenotyping of additional mutants suggested that the GI attenuation might be
linked to a nonsense mutation in tc0600. The molecular mechanism underlying this dra-
matic difference in tissue-tropic virulence is not fully understood. However, isolation of
these mutants demonstrates that distinct chlamydial chromosomal factors mediate chla-
mydial tissue tropism and provides a basis for vaccine initiatives to isolate chlamydia
strains that are attenuated for genital infection but retain the ability to colonize the GI
tract and elicit protective immune responses.
KEYWORDS Chlamydia, gastrointestinal infection, genital tract immunity, intracellular
bacteria, intracellular pathogen, sexually transmitted diseases
Chlamydia trachomatis infection is the most common bacterial sexually transmittedinfection in the United States, with nearly 1.6 million cases reported to the U.S.
Centers for Disease Control and Prevention (CDC) in 2016 (1). Many C. trachomatis
infections are asymptomatic, so the actual number of cases is likely to be much higher
(2–4). When chlamydia infection is diagnosed, it is effectively treated with antibiotics;
however, undetected genital infections in women can persist and ascend, to cause
infection and subsequent inﬂammation in the upper genital tract (5). Upper genital
tract inﬂammation may cause pelvic inﬂammatory disease, salpingitis, tubal scarring,
ectopic pregnancy, and infertility. In addition to the urogenital tract, C. trachomatis
infects the conjunctiva, pharynx, respiratory tract, rectum, and gastrointestinal (GI) tract.
The recent recognition that rectal infections are frequent in women who do not report
traditional rectal chlamydia infection risk factors (6), and the premise that the GI tract
may serve as a site for persisting infection and as a reservoir for urogenital reinfection
(7–10), has renewed interest in understanding the molecular basis of chlamydial GI
colonization and pathogenesis.
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The chlamydial plasticity zone (PZ) is a region of high genetic diversity in the
genomes of otherwise highly conserved Chlamydia spp. (11, 12). Some PZ genes
mediate chlamydial immune evasion, but the functions of most of these genes are
unknown (13–16). Using a murine genital tract infection model, we previously assessed
the virulence of Chlamydia muridarum mutants containing nonsense mutations in
various PZ genes, including three cytotoxin genes (tc0437, tc0438, and tc0439) (17).
These mutants elicited genital infections similar to those caused by their parent, as
assessed by bacterial shedding and duration of infection, although infection with the
mutants generally resulted in fewer occurrences of hydrosalpinx (17). However, be-
cause the chlamydial cytotoxin genes share homology with large clostridial toxin genes
(18), which are key Clostridium difﬁcile GI virulence factors (19), we sought to determine
if the C. muridarum cytotoxin mutants showed altered virulence for GI infection.
In the current study, the pathogenicities of the three cytotoxin nonsense mutants
were compared in two GI infection models by assessing bacterial shedding, anti-
chlamydia antibody responses, and immunity to genital infection. We found that
nonsense mutations in individual cytotoxin genes per se did not alter the virulence of
C. muridarum infection for either genital or GI infections. However, the profound
attenuation of one of the cytotoxin mutants for GI, but not genital, infection was
associated with an additional background nonsense mutation in the conserved chla-
mydial hypothetical protein gene tc0600, suggesting that this gene might be a GI-
speciﬁc virulence factor. Overall, our results show that distinct chromosomal genes
mediate C. muridarum genital and GI infection and suggest that it might be possible to
construct vaccine strains that are attenuated for genital tract infection but are able to
colonize the GI tract to elicit transmucosal genital tract protection.
RESULTS
C. muridarum cytotoxin mutants are virulent in the murine genital tract. The
goal of the current study was to determine if C. muridarum cytotoxin mutants have
tissue-speciﬁc virulence defects. Therefore, it was ﬁrst important to verify the virulence of
all strains in the genital infection model (17) and to measure baseline immune responses
for comparison to GI infections. Mice were intravaginally inoculated with the wild-type
parent strain (WT) or with mutants (TC0437, TC0438, or TC0439) having nonsense muta-
tions in one of the three cytotoxin genes (tc0437, tc0438, or tc0439, respectively), and
infection was monitored by enumerating chlamydiae collected from cervicovaginal
swabs. The magnitude and duration of chlamydial shedding between WT- and mutant-
inoculated animals were similar, with the only signiﬁcant difference detected between
WT and TC0438 at day 10 (P  0.016) (Fig. 1A). Furthermore, the overall immunoglob-
ulin class- and subclass-speciﬁc anti-chlamydia antibody responses elicited by infection
with the mutants was not markedly different from those of the WT, but slight differ-
ences were observed in the titers of some responses (Fig. 1B). Thus, measures of
chlamydial shedding, infection duration, and immunogenicity conﬁrmed that disrup-
tion of individual cytotoxin genes did not overtly impact the virulence of C. muridarum
in the mouse genital tract.
C. muridarum mutant TC0439 displays unique tissue-speciﬁc virulence. Chla-
mydiae have been isolated from the GI tracts of both animals and humans (7). In mice,
C. muridarum establishes long-lasting GI infections characterized by minimal tissue
pathology (10, 20–23). Because C. muridarum cytotoxin genes are homologous to genes
that are critical for the colonization of the GI tract by other bacterial pathogens (24, 25),
we sought to determine if the GI tropism of chlamydial cytotoxin mutants is altered. GI
infections were established by intrarectal (Fig. 2A) or oral gavage (Fig. 2B) inoculation.
The WT produced long-lasting infections by both inoculation routes. GI shedding from
WT-infected mice measured between 103 and 104 inclusion-forming units (IFUs) during
early infection (weeks 1 to 4) and then decreased to 101 to 103 IFUs later in infection
(weeks 5 to 11). The course of GI infections produced by either inoculation route with
mutants TC0437 and TC0438 was remarkably similar to that of the WT, although mice
inoculated intrarectally with TC0438 did resolve GI infection by 8 weeks postinoculation
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(P  0.008). In contrast, the attenuation of TC0439 in both GI infection models was
striking (Fig. 2). Neither intrarectal nor oral gavage inoculation with TC0439 resulted in
productive infection (P  0.001). Thus, TC0439 displayed a unique tissue-restricted
virulence phenotype, retaining full virulence for genital tract infection (Fig. 1) while
exhibiting highly attenuated GI infection (Fig. 2).
Immunological studies corroborate the attenuation of TC0439 for GI infection.
We inferred, from the chlamydial shedding data collected using rectal swabs, that
TC0439 was attenuated for GI infection. An alternative explanation for that observation
is that TC0439 established infection in the upper GI tract or disseminated to distant
tissues and rectal culture failed to detect those infections. We differentiated those
possibilities by measuring the anti-chlamydial antibody responses and the ability of
GI-challenged mice to defend against genital reinfection. Infection of the murine GI
tract with the WT by intrarectal (Fig. 3A) or oral gavage (Fig. 3B) inoculation elicited
robust anti-chlamydia antibody responses. Similar antibody responses developed fol-
lowing infection with TC0437 and TC0438. In contrast, the antibody responses elicited
FIG 1 C. muridarum toxin mutants are virulent in the genital tract. C57BL/6 mice were pretreated with
medroxyprogesterone acetate and challenged with 5  104 IFUs of the WT (n  6) or toxin mutants
(n  6 for each mutant). (A) Vaginal vaults were swabbed at the indicated times, and IFUs were
enumerated on HeLa cell monolayers by immunoﬂuorescence. Data are presented as the geometric
mean standard deviation (SD) of IFUs recovered at the indicated days postinfection. Statistical analysis
revealed differences in bacterial shedding over time among the strains (group-by-day P value, 0.0049).
Comparison of the WT proﬁle to each of the mutant proﬁles revealed that the WT was statistically
different from TC0437 and TC0438 but not TC0439. The differences between TC0437 and the WT
approached statistical signiﬁcance at day 10 (P  0.065) and day 14 (P  0.094), and TC0438 was
signiﬁcantly different from WT at day 10 (P  0.016). No other differences were detected. (B) Sera
collected 49 days following genital infection were analyzed by EB ELISA. Antibody responses are
presented as mean log2 titers  SD for each of the indicated Ig classes. A dashed line indicates cutoff
values for a positive serologic response. The antibody responses were remarkably similar, with the
following exceptions: WT versus TC0437 and WT versus TC0439 IgA titers, P  0.01; WT versus TC0437
and WT versus TC0438 IgG3 titers, P  0.05. No other differences were detected.
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following intrarectal (Fig. 3A) or oral gavage (Fig. 3B) inoculation with TC0439 were
below or slightly above baseline levels of uninfected mice (P  0.02).
The inability of TC0439 to productively infect the GI tract and induce anti-chlamydial
antibodies suggested that its GI virulence was severely impaired. For an independent
virulence measure, we assessed whether GI infection with TC0439 protected against
subsequent genital tract challenge (23). Mice were challenged by either intrarectal or
oral gavage inoculation with the WT or mutant TC0439, and GI infection was monitored
by rectal swab for 11 weeks (Fig. 4A). Approximately 17 weeks postinoculation, mice
were treated with doxycycline to cure residual infection, treated with medroxyproges-
terone acetate, and challenged vaginally with the corresponding chlamydial strain.
Mice infected with the WT, by either intrarectal or gavage inoculation, were markedly
protected against WT genital tract infection (P  0.0005) (Fig. 4B). In contrast, GI
inoculation of mice with TC0439 did not protect against subsequent TC0439 genital
infection. The course of genital infection (chlamydial shedding and infection duration)
in mice receiving a prior GI challenge with TC0439 was remarkably similar to that of
primary genital tract infection with this mutant (Fig. 1A). Moreover, the marginal
anti-chlamydia antibody response elicited by TC0439 following GI infection was in-
creased to a level typically observed following primary vaginal challenge (Fig. 5A and
B). Also, 4 days prior to vaginal challenge (143 days post-GI infection), all GI WT-
challenged mice (5 of 5 intrarectally infected and 4 of 4 infected by gavage) were
vaginal wash positive for anti-chlamydia antibody, whereas of the TC0439-challenged
mice, 0 of 5 rectally infected and 1 of 5 infected by gavage were vaginal wash positive
FIG 2 TC0439 is highly attenuated for GI infection. C57BL/6 mice were challenged by rectal (A) or gavage (B) inoculation with the WT or mutants to measure
virulence for GI infection. For rectal inoculation, 10 l containing 1  105 IFUs was placed intrarectally. Gavage inoculation was accomplished by inoculation
of 100 l containing 1  106 IFUs via a feeding tube. Infection was assessed weekly by swabbing the rectum and counting IFUs on HeLa cell monolayers. Data
are presented as the geometric mean  SD of IFUs at the indicated time points. The number of mice per group is indicated in the ﬁgure. For comparison, the
infection curve for WT rectal (A) and gavage (B) infection is replicated in each panel. (A) Rectal challenge. The test results of the overall interaction effect were
found to be statistically signiﬁcant (P  0.0001). The interaction between TC0437 and the WT was not signiﬁcantly different (P  0.63), and the test of the main
strain effect was not statistically signiﬁcant (P  0.063). The interaction effect for TC0438 and the WT was statistically signiﬁcant (P  0.0001). A comparison
performed for each day found signiﬁcant differences from the WT at day 56 and beyond (P  0.008). Differences at other time points were not signiﬁcant.
TC0439 was signiﬁcantly different from the WT at all time points (P  0.001). (B) Gavage challenge. TC0437 was not found to be signiﬁcantly different from
the WT (interaction, P  0.085; main strain effect, P  0.11); TC0438 was not found to be signiﬁcantly different from the WT (interaction, P  0.19; main strain
effect, P  0.35); and TC0439 was found to be signiﬁcantly different from the WT (interaction, P  0.020; main strain effect, P  0.0001).
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for anti-chlamydia antibody. Collectively, these results conﬁrmed that TC0439 was
highly attenuated for GI infection.
GI attenuation of TC0439 is independent of challenge dose. GI infection estab-
lished by either oral gavage or intrarectal inoculation of the WT resulted in similar
infection courses, based upon rectal bacterial shedding and serology (Fig. 2 and 3).
Therefore, we used the intrarectal inoculation model to compare the infectious dose
FIG 3 TC0439 fails to elicit robust antibody responses following GI infection. As an additional assessment of infection, the antibody responses of GI infected
mice (Fig. 2) were measured. Sera collected 81 days following rectal (A) or gavage (B) challenge were analyzed by EB ELISA. The number of mice per group
is indicated on the ﬁgure. Antibody responses are presented as the mean log2 titers SD for each of the indicated Ig classes. Dashed lines indicate cutoff values
for positive serologic responses. The antibody responses of mice infected following rectal or gavage inoculation with mutant TC0439 were negative or just
above background responses and were signiﬁcantly lower than responses elicited by WT infection (P  0.016 for all Ig classes tested, except IgG3, which was
not signiﬁcant, P  0.05). Antibody responses elicited by TC0437 and TC0438 were not signiﬁcantly different from that of the WT (P  0.05), except for TC0438
rectal challenge (IgG2b, IgG2c, and IgA, P  0.008).
FIG 4 GI infection with TC0439 does not protect against genital challenge. (A) Mice were infected by
either gavage or intrarectal inoculation with the WT or TC0439, and GI infection was monitored by
enumerating IFUs from rectal swabs. (B) At 118 days following GI infection, mice were treated with
doxycycline for 10 days, rested 2 weeks, treated with medroxyprogesterone acetate and then rechal-
lenged vaginally with the homologous strain. Data are presented as the geometric mean  SD. The
number of mice per group is indicated on the ﬁgure. As shown previously (Fig. 1), mutant TC0439 was
highly attenuated for GI infection (A) (TC0439 compared to the WT by both gavage and rectal
inoculation, P  0.0001). Gastrointestinal infection (by gavage or intrarectal inoculation) with the WT
conferred striking protective immunity (decreased bacterial shedding and shorter duration of infection)
to vaginal challenge, whereas neither rectal nor gavage inoculation of TC0439 protected against vaginal
challenge (P  0.0005) (B). All mice receiving GI (rectal or gavage inoculation) WT infection were
protected from the development of hydrosalpinx upon vaginal challenge.
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responses of the WT and TC0439 (Fig. 6). For the purpose of calculating a 50% infectious
dose (ID50), we evaluated infection at 21 days postchallenge. Based upon our previous
experiments (Fig. 2), 21 days postchallenge was sufﬁcient to establish, but not resolve,
infection. The dose response to WT infection was assessed by challenging mice by
intrarectal inoculation with either 102, 103, 104, or 105 IFUs. All mice challenged with 105
FIG 5 Antibody response of TC0439 GI-infected mice increases following vaginal rechallenge. Sera were
collected from the WT- and TC0439-infected mice described in the legend to Fig. 4 and analyzed by EB
ELISA. Antibody responses are presented as mean log2 titers  SD for each of the indicated Ig classes.
Dashed lines indicate cutoff values for positive serologic responses. (A and C) Anti-chlamydia antibody
responses of mice challenged intrarectally (A) or by gavage (C) at 146 days following GI challenge. (B and
D) Sera were collected 21 days following vaginal rechallenge of mice infected rectally (B) or by gavage
(D) and analyzed by EB ELISA. WT GI infection (both rectal and gavage infection) elicited robust
anti-chlamydia antibody responses, and titers did not signiﬁcantly change upon vaginal rechallenge
(P  0.05). TC0439 elicited signiﬁcantly lower anti-chlamydial antibody responses than the WT (P 
0.032 for IgG1, IgG2b, IgG2c, and IgA but not for IgG3) following primary infection either rectally or by
gavage (A and C), and antibody responses following vaginal challenge rose to levels comparable to that
of the WT (rectal challenge in panel B, P  0.05 for all Ig class and subclass responses; gavage challenge
in panel D, P  0.032 for IgG2b, IgG2c, and IgA, and P  0.05 for IgG1 and IgG3).
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or 104 IFUs became infected, whereas intrarectal challenge with 103 or 102 IFUs resulted
in GI infection of 3 of 6 and 0 of 6 mice, respectively. The estimated ID50 for WT GI
infection by intrarectal inoculation was 102.97 IFUs (95% conﬁdence interval [CI], 102.23
to 103.65). Challenge doses of 104, 105, 106, 107, and 108 IFUs were used to assess the
dose response of TC0439. None of the doses were sufﬁcient to infect 100% of the mice.
Five of six mice inoculated with 108 IFUs were infected, but the shedding of chlamydiae
from these animals was much lower than that of animals infected with WT. The
estimated ID50 for TC0439 GI infection by intrarectal inoculation was 106.85 IFUs (95%
CI, 106.18 to 107.59), which was signiﬁcantly different from that of the WT (P  0.0003).
Not only was TC0439 more than a 1,000-fold less infectious than the WT for GI infection,
but mice that did become culture positive following challenge with high doses of the
mutant shed 100-fold fewer chlamydiae than mice infected with the WT. Ninety-four
days following challenge, sera were analyzed for anti-chlamydial antibody. All culture-
positive (infected) mice that had been inoculated with either the WT or mutant TC0439
were seropositive, whereas none of the culture-negative mice seroconverted, thus
verifying the infectivity data.
Background chromosomal nonsense mutation might explain profound GI at-
tenuation. TC0439 was generated by four sequential rounds of chemical mutagenesis
and contains 28 point mutations in comparison to the WT, including nonsense muta-
tions in tc0439 and the conserved chlamydial open reading frame (ORF) tc0600 (Table
1). To determine if GI attenuation of TC0439 might be linked to the inactivation of
tc0439, tc0600, or other missense mutations, we evaluated the phenotypes of two
additional mutants, TC0437/0439 and GuaB (Table 1; see Fig. 8), in the genital tract and
GI infection models. TC0437/0439 contains nonsense mutations in tc0437 and tc0439,
while GuaB contains nonsense mutations in guaB and tc0600. Genital infection resulting
from vaginal challenge with TC0437/0439 and GuaB resembled WT infection (Fig. 7A),
although chlamydial shedding was somewhat reduced compared to that of the WT
(P 0.05). However, when the mutants were compared to the WT in the rectal infection
model, TC0437/0439 behaved similarly to the WT, though shedding was somewhat
reduced (P  0.05), whereas the mutant GuaB was strikingly attenuated (P  0.00001),
with few animals displaying evidence of productive infection (Fig. 7B). The marked
attenuation of TC0439 and GuaB for GI infection provides compelling evidence that
distinct chromosomal genes strongly impact the tissue-speciﬁc virulence of Chlamydia.
Furthermore, a shared mutation in the genomes of TC0439 and GuaB (Table 2; Fig. 8)
resulted in dramatic GI attenuation.
FIG 6 ID50 of TC0439 for GI infection is 1,000-fold greater than that of the WT. Mice were challenged
intrarectally with the indicated doses of either the WT or mutant TC0439, and infection was monitored
by swabbing the rectum and enumerating the IFUs on HeLa cell monolayers. Data are presented as the
geometric mean  SD at day 21 postchallenge. The calculated ID50 for the WT is 102.97 (95% conﬁdence
interval, 2.23 to 3.65), and that for TC0439 is 106.85 (95% conﬁdence interval, 6.18 to 7.59); P  0.0003.
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DISCUSSION
Chlamydia spp. colonize multiple distinct organ system tissues (7). In humans, C.
trachomatis strains most frequently infect the cervix and urethra but can also colonize
the pharynx, conjunctiva, and GI tract. Chlamydial GI infections are often asymptomatic,
can persist without overt signs or symptoms of infection, and are less sensitive to the
standard-of-care antibiotic therapy (single-dose azithromycin) (6, 8, 9, 26–28). Because
of the propensity of GI infections to persist, even following antibiotic therapy, it has
been proposed that chlamydial GI infection is a reservoir for genital tract reinfections
(7–10). The recent realization that chlamydia GI infections are common in women has
renewed interest in understanding the pathogenesis and the pathological conse-
quences of GI chlamydial infection and in elucidating the role of these infections in the
epidemiology of the more problematic female urogenital infections.
The murine model using C. muridarum is an ideal experimental system to study
tissue-speciﬁc virulence factors of Chlamydia. C. muridarum colonizes both the genital
and GI tracts and produces distinct tissue-speciﬁc experimental outcomes that mimic
many characteristics of human genital and GI infections. GI colonization with C.
muridarum can be established by oral or rectal inoculation or as the result of dissem-
ination via the blood from a genital infection (29). GI infection often persists and is
characterized by long-term shedding of infectious chlamydiae in the absence of overt
inﬂammation (10). Conversely, genital infection is characterized by the shedding of
abundant infectious chlamydiae and signiﬁcant inﬂammation, and infection naturally
resolves in about 4 weeks (30, 31).
A few studies have used the murine infection model to study chlamydial tissue
tropism (32–34). In one recent study, the C. muridarum plasmid gene pgp3 was
associated with GI but not genital infection (34). However, our current study clearly
demonstrates that tissue-speciﬁc virulence factors are also encoded on the C. muri-
darum chromosome. We speculate that a nonsense mutation in the chromosomal gene
tc0600 was independently associated with GI-speciﬁc attenuation, but further genetic
studies are needed to precisely map the chromosomal gene(s) responsible for the
GI-speciﬁc attenuation. Interestingly, polymorphisms in the C. trachomatis tc0600 or-
tholog, ct326, which encodes a putative secreted inclusion membrane protein (35),
have been associated with GI tropism in humans. A 111-nucleotide in-frame insertion
in ct326 of C. trachomatis serovar G is correlated with the ability of this strain to infect
the GI tract, and strains lacking this insertion are associated with cervical but not GI
infection (36). This 111-nucleotide region is conserved in C. muridarum tc0600.
Although we associated inactivation of tc0600 with GI attenuation, the TC0439 and
GuaB mutant strains share seven additional nonsynonymous mutations (Table 2; Fig. 8).
The shared mutations suggest that these isolates were derived from a common parent
that was present in the population after the ﬁrst few rounds of mutagenesis. Four of
these mutations are predicted to cause nonconserved amino acid changes in TC0054
TABLE 1 Summary of SNPs in C. muridarum mutants
Mutant
strain
Total no. of
mutations
No. of silent
mutations
No. of missense
mutations
No. of intergenic
mutations
Nonsense mutation characteristics
Gene
Genomic
position
Nucleotide
change
Amino acid
change
TC0437 44 13 29 0 tc0412 473585 C¡T Q¡STOP
tc0437 506777 C¡T Q¡STOP
TC0438 35 6 26 0 tc0412 473585 C¡T Q¡STOP
tc0438 516403 C¡T Q¡STOP
tc0450 549083 C¡T R¡STOP
TC0439 28 10 13 3 tc0439 527311 C¡T Q¡STOP
tc0600 717761 G¡A Q¡STOP
TC0437/0439 53 15 35 0 tc0412 473585 C¡T Q¡STOP
tc0437 506777 C¡T Q¡STOP
tc0439 526979 G¡A W¡STOP
GuaB 29 8 17 2 tc0443 541698 G¡A Q¡STOP
tc0600 717761 G¡A Q¡STOP
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(penicillin binding protein), TC0290 (hypothetical), TC0312 (glycosyl hydrolase, GlgX),
and TC0473 (peptide ABC transporter, permease protein). These genes have not been
linked to C. muridarum virulence or reported to be plasmid regulated (37–39). Identi-
fying the speciﬁc allele(s) responsible for attenuation of the TC0439 and GuaB mutant
strains is essential to understanding the mechanism of GI attenuation. Unfortunately,
complementation is contraindicated for differentiating the potential mutant alleles,
because the plasmid is a C. muridarum GI virulence factor (32) and negative comple-
mentation results could indicate a failure to complement or cis-acting effects on the
plasmid. Perhaps one method that could be used to circumvent this concern is the
ﬂuorescence-reported allelic exchange mutagenesis (FRAEM) approach developed in C.
trachomatis to inactivate tc0600, which would permit generation of targeted chromo-
somal deletions while maintaining the endogenous plasmid (40).
Also of interest is the nonsynonymous single-nucleotide polymorphism (SNP) in
FIG 7 C. muridarum strains with nonsense mutations in tc0600 are highly attenuated for GI infection. (A)
Mice were pretreated with medroxyprogesterone acetate and challenged with 5  104 IFUs of C.
muridarum WT (n  5), GuaB (n  10), or TC0437/0439 (n  5). Vaginal vaults were swabbed at the
indicated times, and IFUs were enumerated on HeLa cell monolayers by immunoﬂuorescence. Data are
presented as the geometric mean  SD of IFUs recovered at the indicated days postinfection. Both
mutants displayed vaginal infections similar to that of the WT, although somewhat lower levels of
chlamydial shedding of the mutants than of the WT were observed. The overall interaction effect
between strains was not different (P  0.22). However, results of tests comparing mutant GuaB and
TC0437/0439 and WT main effects were statistically signiﬁcant (P  0.005). (B) Mice were inoculated
intrarectally with 10 l containing 1  105 IFUs of either the WT (n  8), GuaB (n  10), or TC0437/0439
(n  8). Infection was assessed weekly by swabbing the rectum and counting the IFUs on HeLa cell
monolayers. Data are presented as the geometric mean  SD of IFUs at the indicated time points. The
overall interaction effect between the strains was not statistically signiﬁcant (P  0.11); however, results
of tests comparing GuaB to WT, TC0437/0439 to WT, and GuaB to TC0437/0439 main effects were
signiﬁcant (P  0.0001, P  0.014, and P  0.0006, respectively).
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tc0439 contained in the GuaB mutant (amino acid [aa] residue 3114 of the TC0439
mutant), which results in a glycine-to-aspartic acid change. Sequence comparison of
cytotoxin genes from a variety of pathogens shows that this glycine residue is highly
conserved, and thus mutating such a highly conserved residue could result in the loss
of toxin function. Because this tc0439 mutation is found in the GuaB mutant and the
TC0439 mutant contains a premature stop codon in tc0439, perhaps the attenuated GI
infection phenotype observed with these two mutants was due to loss of function of
the tc0439 toxin. However, the TC0437/0439 mutant, which contains a premature stop
codon in tc0439 upstream of the nonsynonymous SNP in tc0439 contained in the GuaB
mutant, remains infectious for the GI tract and thus does not corroborate that notion.
The multiple mutations present in our strains confound the identiﬁcation of a speciﬁc
gene mutation responsible for the tissue-tropic phenotype with absolute certainty, and
the infection phenotype that we report could be multifactorial. Nevertheless, the very
robust in vivo infection phenotype provides a compelling basis for further studies to
elucidate the molecular mechanism of tissue-speciﬁc infection.
Short-lived protective immunity develops following human C. trachomatis genital
infection (41–43), whereas in mice, protective immunity is quite long-lasting (30, 44, 45).
This dissimilarity in the duration of immunity between humans and mice is not
understood and could be multifactorial. However, our observations and those of others
showing that murine GI C. muridarum infection produces nearly sterilizing immunity
against vaginal challenge (Fig. 4) (23) may be central to elucidating the immunological
mechanisms responsible for the durability of chlamydial immunity. Mice infected
TABLE 2Mutations present in both TC0439 and GuaB mutant strains
Genomic
position Gene ID Description
Nucleotide
change
Amino acid
change
62823 tc0054 Penicillin binding protein G¡A Gly¡Glu
126188 Intergenic between tc0106 and tc0107 Intergenic C¡T Intergenic
224779 tc0191 Hypothetical protein G¡A Gly¡Gly
233168 tc0197 Polymorphic membrane protein, PmpD G¡A Glu¡Lys
292616 tc0250 Hypothetical protein C¡T Val¡Ile
349120 tc0290 Hypothetical protein G¡A Ser¡Phe
369812 tc0312 Glycosyl hydrolase, GlgX G¡A Ser¡Phe
573799 tc0473 Peptide ABC transporter, permease protein C¡T Pro¡Leu
717761 tc0600 Hypothetical protein G¡A Gln¡STOP
FIG 8 Venn diagram of the missense and nonsense mutations found in TC0439 and GuaB. An asterisk
represents a stop codon.
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vaginally with C. muridarum concurrently acquire GI infection and remain GI tract
positive long after genital infection has resolved (46). Perhaps, then, persisting GI
infection is a vital component for the robust durability of protective immunity and
could be key to developing an efﬁcacious vaccine to prevent chlamydial genital
infection. We clearly showed that genital and GI infection tropisms were separable by
identifying a mutant that infected the genital tract normally but was highly attenuated
for GI infection. While that is not the phenotype desired for a chlamydial vaccine, it
does provide proof of principle for the identiﬁcation of strains that possess altered
tissue tropism. Identiﬁcation of strains that infect the GI tract but are attenuated for
genital tract infection would allow for direct testing of the hypothesis.
By using animal models of infection, a more complete understanding of the
contribution of chlamydial GI infection to the robust and long-lasting protective
immunity that develops against genital infection will emerge. However, well-designed
epidemiological studies and correlative immunological analysis of subjects with chla-
mydial urogenital and GI infections are needed to determine if a link exists between GI
infection and protective immunity to genital chlamydia infection in humans.
MATERIALS AND METHODS
Chlamydia strains. C. muridarum wild-type (WT) (GenBank accession AE002160.2) and C. muri-
darum mutants TC0437, TC0438, TC0439, GuaB (17), and TC0437/0439 (see Table S1 in the supplemental
material) were propagated in HeLa 229 (47) cells, and elementary bodies (EBs) were puriﬁed by
discontinuous Renograﬁn gradient centrifugation. Table 1 summarizes the single-nucleotide polymor-
phisms (SNPs) found in the mutants (17) (Table S1).
Generation and whole-genome sequencing of C. muridarum TC0437/0439. TC0437 (Table 1) was
mutagenized with 8 mg/ml ethyl methanesulfonate (EMS), and a clone that contained a nonsense
mutation in tc0439 (TC0437/0439) was identiﬁed, puriﬁed, and sequenced as described previously (17).
SNPs and nucleotide insertions and deletions (indels) were mapped by aligning the TC0437/0439 and C.
muridarum reference genomes (GenBank accession number AE002160.2) using Bowtie2. SNPs/indels
were called using a Samtools mpileup function, and the remaining ambiguous sequences with low-
quality scores were resolved by Sanger sequencing.
Mice. Female C57BL/6 mice, 6 to 8 weeks old, were purchased from Jackson Laboratories (Bar Harbor,
ME) and maintained in the animal facilities at the University of Arkansas for Medical Sciences (Little Rock,
AR). All experimental procedures were performed in accordance with protocols approved by the UAMS
Institutional Animal Care and Use Committee.
Genital infection. Five days before genital infection, mice were injected subcutaneously with 2.5 mg
of medroxyprogesterone acetate (Depo-Provera; Greenstone, LLC) to synchronize the estrous cycle of
experimental mice. Mice were then infected vaginally with 5  104 IFUs of the WT or mutants (48, 49).
Infections were monitored by inoculating cervicovaginal swab samples onto HeLa 229 cell monolayers,
and IFUs were visualized and counted as described in detail previously (48, 49).
GI infection. Two routes of inoculation, intrarectal and gavage, were used to assess the pathoge-
nicity of the mutants for the murine gastrointestinal tract. For rectal inoculation, the tip of a micropipette
was gently inserted approximately 5 mm into the rectum, and 10 l of a buffered suspension (250 mM
sucrose, 10 mM sodium phosphate, and 5 mM L-glutamic acid, pH 7.2) (SPG) containing 1  107 IFUs/ml
of WT or mutants (1  105 IFU, total challenge dose) was deposited. Infection was monitored by
collecting rectal swabs at weekly intervals. Calgiswabs (Puritan) were wetted with SPG, inserted into the
rectum, and rotated 8 times clockwise and 8 times counterclockwise. Swabs were then placed in a tube
containing 0.5 ml SPG and two 4-mm glass beads and vortexed at 1,400 rpm for 3 min. The swabs were
removed, an additional 0.5 ml of SPG was added, and samples were stored at 80°C. Infection was
monitored by counting IFUs as described previously (48).
A ﬂexible 20-gauge feeding tube (Instech) was used to challenge mice by gavage. Mice were
inoculated with 1  106 IFUs of the WT or mutants by depositing 100 l of a suspension of 1  107
IFUs/ml in SPG into the stomach. Gastrointestinal infection was monitored by rectal swabs, and IFUs were
counted as described above (48).
Vaginal challenge of GI infected mice. Mice were infected with either the WT or TC0439 by rectal
or gavage inoculation, and infection was monitored weekly. One hundred eighteen days following GI
infection, mice received daily intraperitoneal injections of 300 g of doxycycline for 10 days, which is
sufﬁcient to cure GI infection (9). The mice were then rested for 2 weeks to eliminate any residual effect
of the antibiotic treatment, and rectal swabs conﬁrmed that the mice were culture negative for
chlamydiae. The mice were then treated with medroxyprogesterone acetate and challenged vaginally
with the homologous strain (WT or TC0439) as described above for genital infection.
ELISA. Anti-chlamydial antibody was measured by enzyme-linked immunosorbent assay (ELISA)
using formalin-ﬁxed, density gradient-puriﬁed WT EBs as the antigen (30, 49).
Statistical analyses. Analyses of bacterial shedding data were performed using nonparametric
longitudinal analysis methods (50). The methods are rank based and require fewer distributional
assumptions than parametric methods. The models included terms representing group (chlamydial
strain), time (day of measurement), and a group-by-time interaction. As with other factorial models, the
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interaction effect was evaluated ﬁrst, and, if not signiﬁcant, the overall group and time effects could be
assessed. However, in the case of a signiﬁcant interaction, the time proﬁles of each mutant were compared
to those of theWT, separately. Mutants whose time proﬁle differed from that of theWTwere examined further
by comparing themutant to theWT at each time point. Wilcoxon rank sum tests were used for these analyses.
Wilcoxon rank sum tests were also used to compare mutants to WT with respect to antibody titer data.
Finally, probit regression models were used to obtain ID50 estimates and corresponding 95% conﬁdence
limits. P values of 0.05 were considered to be statistically signiﬁcant. No adjustment for multiple
comparisons was made.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/IAI
.00141-18.
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